We are excited to announce the 14th Anti-Infectives Partnering & Deal-Making Conference, which will take place July 13-14, 2017 in Baltimore, MD. Recently launched programs such as CARB-X and the expanded pool of research and development funds brought about by the U.S. National Action Plans on Combating Antibiotic Resistant Bacteria (CARB) demonstrate recognition that the anti-infective pipeline is precariously fragile. These complimentary programs, as well as other international programs, seek to address funding and market limitations that occur at all phases of drug development, from early stage, hit to lead identification, to late stage clinical development. However, despite the technical and monetary resources available to developers the challenges and risks inherent in anti-infective development loom unabated.
We invite you to join us for this two day event as we discuss the types and availability of economic incentives to spur innovation and development of therapies to address rapidly emerging global health threats; international partnering and funding opportunities; and non-traditional approaches and technologies, including innovative clinical trial strategies for the development of anti-infectives. Over the course of this meeting attendees will have ample opportunity to engage and network with speaker and panelists.
- Plenary Session: Responding to Emerging Infectious Diseases on the Global Stage
- Non-Traditional Approaches and Technologies in Anti-Infectives
- Regulatory Considerations for Drug Development
- Economic Drivers Moving Drug Development Forward
- Panel: Funding & Partnering with US Government Agencies
- Panel: Pricing and P&T Committee’s Role in Determining Novel Antibiotic Usage
- Panel: Pushing and Pulling: What Incentives Help Spark Innovation in Antibiotic Drug Discovery and Development?
- General Session: Public/Private Partnerships in Support of Global Health
We hope to see you there!
The 2017 Advisory Committee
|2017 Program Director|
|Mark Albrecht, BARDA, HHS|
|2017 Advisory Board Members|
|Mladen Tomich, Decision Resources Group|
|Rahul Dhanda, T2 Biosystems|
|Joseph Larsen, BARDA, HHS|
|Vikas Goyal, SR One|
|Gabriela Lavezzari, Duke University|
|Mahmoud Ghannoum, Case Western Reserve University|
|John Clerici, Tiber Creek Partners, LLC|
|Stephen Zinner, Mount Auburn Hospital|
|Glenn Tillotson, Cempra|
|Jonathan Lourie, Duane Morris LLP|
|Vu Truong, Aridis Pharmaceuticals|
|Eszter Nagy, Arsanis|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
WIB is an organization of professionals committed to promoting careers, leadership, and entrepreneurship for women in the life sciences. The DC/Baltimore Chapter is dedicated to creating opportunities for women in life science industry, encouraging women to translate novel discoveries into products, and promoting dynamic women in their careers.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.